# Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

> **NCT01359644** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 350 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** PSI-7977
- **DRUG:** Daclatasvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01359644
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-01
- **Final completion:** 2013-10
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2015-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359644, "Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01359644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*